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The Informed Consent Process in Genetic Family Studies 
 





The informed consent process provides protection by ensuring that potential research 
subjects understand the goals of the research project they are being asked to 
voluntarily partake in as well as the risks associated with the study. We examined 
subjects’ comprehension and ability to identify issues explicitly raised during the 
consent process that was conducted as part of their participation in a genetic family 
study (GFS). We employed cross-sectional design by providing a short, self-
administrative questionnaire to 246 participants recruited from families enrolled in the 
Extended Family Investigation of Nephropathy and Diabetes (EFIND) study 
conducted at the University of Texas Health Science Center. Participants responded to 
the questionnaire directly after their enrollment in the EFIND study. The 
questionnaire consisted of multiple-choice questions and focused on the 
understanding of the purposes, procedures, and risks associated with their 
participation in the EFIND study. These questions were formulated to reflect basic 
information presented to subjects through the consent process. Responses to questions 
were expressed as percentages, placing equal weight on each response. Participants 
were Mexican-American, 62.3% female and averaged 35.2 ±12.7 years old (range: 
18-76). Our findings showed that the average comprehension score was 58. About 
30% of the participants did not know the name of the study, and 70% did not identify 
all elements related to the study procedures. The most striking finding was the lack of 
understanding concerning the social risks associated with participation in EFIND. 
While 35.1% of participants identified all potential physical risks, only 1.3% could 
identify all of the social risks. Our findings showed that participants comprehension 
score was significantly associated with their level of education and income. We 
conclude that using the informed consent process to communicate research social 
risks to subjects participating in GFS has some limitations. Future research directed at 
improving risk communications to subjects of low socioeconomic levels participating 




In accordance with Federal regulations, no investigator may involve human subjects 
in research without obtaining informed consent from the subject or the subject’s 
legally authorized representative.2 A consent form is a legal document which contains 
information to help the prospective research subject make an informed and voluntary 
decision about participation in a study. An informed participant is one who fully 
understands the research procedure, purpose, and risks of his or her participation.3 
The informed consent process has been helpful in conducting clinical research; 
however, in the case of genetic family studies (GFS), researchers face complicated 
ethical issues.4 Genomic research aims to identify genes that may be associated with 
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the development and progression of common chronic diseases such as diabetes and 
associated kidney complications. Using GFS design involves families and population-
based sampling, allowing investigation of both genes and environment, separately or 
together, and allows valid inference to the wider population. GFS shifts the focus 
from the traditional individual model to a family model. In the traditional research 
model, subjects have no ties to other research participants, information learned from 
the research affects only the subjects, and subjects give their consent to be studied as 
individuals. By contrast, in the family studies model, subjects have ties to other 
research participants because of shared genetic heritage. In addition, information 
learned from the research affects the whole family, and other family members 
unwillingly become part of the study without their consent.5 
 
There are, however, ethical challenges in ensuring adequate human subject protection 
and addressing participant concerns regarding such research. The use of an 
individual’s genetic information has the potential to affect negatively not only the 
individuals and their families, but also population groups with which the subject is 
associated.6 When the sample is identifiable, there is concern that the donor’s privacy 
will be violated7 leading to the scrutiny, prejudice, coercion and judgment of others 
and loss of insurability and employment.8 If the sample is unidentifiable, there is a 
possibility that a subject’s specimen could be used for future research, which the 
donor finds objectionable due to social or religious norms within his or her sub-
culture. Social repercussions of GFS also put racial and ethnic groups at risk due to 
the potentially stigmatization of specific populations.9 Additionally, in pedigree 
studies, non-paternity and non-maternity may also be unexpectedly revealed, altering 
family relationships evermore. Because of these social, economic, legal, and 
psychological ethical challenges,10 communicating research on social risks and ethical 
issues to enrolled subjects is vital to ensure informed and voluntary participation.11 
Not much is known about the utility of the informed consent process in genetic family 
studies. We examined subjects’ comprehension of information related to their 




Subjects and Procedures 
Participants were recruited from families enrolled in the EFIND study conducted at 
the University of Texas Health Science Center (UTHSCSA). The EFIND study aimed 
to establish complex pedigrees by enrolling extended family members that 
participated in the initial FIND study to identify gene(s) involved in the development 
and progression of diabetic nephropathy (DN) in Mexican-Americans (MA). The 
EFIND study inclusion criteria entail recruiting probands who have advanced DN and 
have both parents living and willing to participate in the study and/or at least one 
living sibling with type 2 diabetes mellitus (T2DM) willing to participate in the study. 
Siblings that are either “concordant” (diagnosed with DN) or “discordant” (diagnosed 
with T2DM for 10+ years without DN) are enrolled. A total of 246 subjects were 
enrolled in EFIND. 
 
In this paper, we report the results obtained from subjects participating in the EFIND 
study to assess subjects’ understanding of the study’s protocol, and of the risks 
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associated with their participation. After informed consent was obtained from all 
participants, blood and urine samples were collected to measure clinical phenotypes 
and to isolate DNA for genetic analysis. The process of obtaining informed consent 
lasted for an average of 35 minutes, and was performed by a trained study coordinator 
experienced in conducting GFS. The consent form was seven-pages long and read at a 
6th-grade level. Subjects were given the form to read, and subsequently the study 
coordinator actively reviewed all of the information and answered participants’ 
questions. The study staff specifically presented information to participants such as 
how confidentiality and privacy will be protected. In addition, they emphasized that 
all information about subjects’ DNA, blood and urine samples, and cell culture will be 
kept confidential and will be assigned an identification number. The study staff also 
asked subjects about their preferences concerning disclosure of the study results. The 
consent form of the EFIND study included multiple-choice questions asking 
participants about their preferences in (1) receiving their lab results, (2) receiving 
their genetic results, and (3) participation in future research. 
 
All participants were offered a short self-administrative structured questionnaire 
directly after their enrollment in the EFIND study. The purpose of the questionnaire 
was to determine how much information participants have comprehended about the 
study’s protocol, and about the physical and social risks as described in the consent 
form. We selected to offer the questionnaire directly after enrollment in order to 
minimize the lag time between the information provided to them during the consent 
process and their responses to our questions. The questionnaire was previously test 
piloted using 30 subjects and revised accordingly. The multiple choice questions were 
formulated to reflect basic information presented to subjects through the consent 
process. Choices for each question included sentences simply extracted from the 
consent form with minor rewording. Six questions were intended to test subjects’ 
understanding as it relates to the purpose and procedures of the study. Three questions 
addressed potential physical and social risks associated with GFS. Two questions 
assessed subjects’ perception about the purpose of the consent form. In addition, the 
questionnaire gathered data on basic demographic information such as level of 
education, income, age, and gender. Subjects’ responses to questions about personal 
health information and voluntary participation are not part of this report. These 
responses focused on different aspects of the study and will be presented in future 
publications. 
 
Study Design and Procedures 
We employed a cross-sectional study design. On average, administering the 
questionnaire required about 15 minutes; it was conducted in English or Spanish 
according to participants’ individual preferences. Subjects had no major health 
impairment that would impede their participation. The Institutional Review Board at 
UTHSCSA approved the study protocol. 
 
Study variables included subjects’ (1) demographic characteristics such as gender, 
age, level of education and income, (2) responses to EFIND study goals and 
procedures, (3) response to the physical and social risks and (4) responses to the 
purpose of the consent form. The following is a brief description of our approach for 
collecting and analyzing data related to these variables. 
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Data analysis 
Respondents were asked to circle all valid responses. Responses to questions were 
expressed as percentages with equal weight given to each answer choice. The average 
score for each subject was calculated. For example, one question asked participants to 
identify all of the physical risks associated with the study based on what they learned 
during the consent process. The answer choices were the following: 
 
a) bleeding and bruising at the site were blood was drawn, 
b) temporary, local discomfort that accompanies all needle sticks,  
c) infection at the site where blood was drawn,  
d) dizziness when the blood sample is taken, but this is temporary 
and mild, and  
e) I do not know. 
 
To receive a complete score (100), participants had to identify all four physical risks. 
Each question was scored individually in this manner, and then the averages were 
combined to represent the “average comprehension score” for the questionnaire. 
Descriptive statistics such as frequency distribution and means were applied to 
analyze categorized and continuous variables. Associations between categorical 
variables in the form of contingency tables were examined using a χ2-test. Correlation 
between the average comprehension score and some selected demographic variables 
were also tested. The software package SPSS (V9) was used for analyzing 




Of the 246 participants enrolled in the EFIND study, 61% (n=151) participated in the 
self-administrative questionnaire. Participants were 62.3% female and averaged 35.2 
±12.7 years old (range: 18-76). About 66% of participants were not formally educated 
beyond high school, 24.5% reported a household income < $20,000. 
 
Responses to EFIND study goals and procedures 
(See Table I) About seventy percent (70.9%) of the participants identified the name of 
the study, while about one-third of the subjects could not. When asked about the goals 
of the study, 17.3% identified both goals: the genetic and ethical aims. Eighty percent 
(80%) indicated that the study was aimed at examining the genetics of diabetes, and 
2.7% did not know. 
 
Subjects were asked to choose all items related to the study’s procedure: (1) an 
interview to review medical history and establish a family tree, (2) review medical 
records, (3) draw blood, (4) collect a urine sample and (5) obtain blood pressure, 
height and weight. 
 
About thirty percent (31.8%) of the participants identified all five items of the study 
procedures. About twenty percent (19.9%) identified four items, 23.2% identified 
three items, and 10.6% identified two items. About 14% identified one item. 
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 Frequency (%)  
N=151  
Name of Study:  
Identified the name of the study 107 (70.8) 
Did not know the name of the study 44 (29.3) 
Purpose of Study:  
Identified both purposes 26 (17.3) 
Identified one purpose 120 (80) 
Did not know  4 (2.7) 
Study Procedures:  
Identified all procedures 48 (31.8) 
Identified 4/5 procedures 30 (19.9) 
Identified 3/5 procedures 35 (23.2) 
Identified 2/5 procedures 16 (10.6) 
Physical Risks:  
Identified all physical risks 53 (35.1) 
Identified 3/4 physical risks 11 (7.3) 
Identified 2/4 physical risks 21 (13.9) 
Identified 1/4 physical risks 54 (35.8) 
Did not know physical risks 12 (7.9) 
Social Risks:  
Identified all social risks 2 (1.3) 
Identified 3/4 social risks 21 (14) 
Identified 2/4 social risks 16 (10.7) 
Identified 1/4 social risks 80 (53.3) 
Did not know social risks 31 (20.7) 
Table I: Subjects’ understanding of the study protocol, physical and social risks 
 
Response to the physical and social risks 
(See Table I) Participants were asked to choose all possible physical risks associated 
with their participation based on their understanding of the materials presented to 
them through the consent form. Potential physical risks included: 
 
(1) bleeding and bruising at the site where your blood was drawn. 
(2) temporary, local discomfort that accompanies all needle sticks. 
(3) infection at the site where blood was drawn. 
(4) dizziness when the blood sample is taken. 
 
About one third of the participants (35.1%), identified all four potential physical risks 
compared to 35.8% who identified only one item. About eight percent (7.3%) 
recognized three items, and 13.9% chose two items. 
 
Participants were also asked to list all possible social risks associated with their 
participation in GFS based on information presented to them through the consent 
form. These social risks are the following: 
 
(1) Genetic analysis may reveal whether or not the parent of a child 
is the actual biological parent. 
(2) There is no way to ensure absolute protection of the privacy of 
genetic information. 
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(3) Anxiety may occur from knowing of an increased risk for kidney 
disease or diabetes. 
(4) Discrimination by health insurers and employers may occur. 
 
Participants’ responses were striking. Only 1.3% of subjects identified all four social 
risks. Whereas 53.3% identified one risk, 14% chose three items, and 10.7% of the 
subjects selected two items. Twenty percent (20.7 %) said they do not know. 
 
 Frequency (%) 
Purpose of Consent Form:  
Identified both purposes 61 (40.4) 
Thought purpose was to understand goals/procedures/risks and 
benefits 
45(29.8) 
Thought purpose was to ensure voluntary participation 42(27.8) 
Did not know purposes 3(1.99) 
When to Sign Consent Form:  
Identified all reasons 49(32.5) 
Identified 3/4 reasons 5(3.3) 
Identified 2/4 reasons 15(9.9) 
Identified 1/4 reasons 73(48.4) 
Did not know reasons 9(5.9) 
Table 2: Subjects’ responses regarding purpose of the consent form  
 
Responses to the purpose of the consent form 
(See Table 2) Participants were asked about the purpose of the consent form and when 
they should sign it. Forty percent (40.4%) of the subjects indicated that the purpose of 
the consent form was to understand the study protocol and to ensure voluntary 
participation. Fifty seven percent (57.6%) identified one purpose, and about 2% did 
not know. Four reasons were listed as to why participants should sign the consent 
form:  
 
(1) To decide to take part in this research study.  
(2) To authorize the collection, use and disclosure of protected 
health information.  
(3) To reiterate that all questions about the study have been 
answered. 
(4) To understand all of the information given about the study, the 
use, and the disclosure of health information. 
 
Of the four reasons, the item “decided to take part in the study” was chosen with the 
highest frequency (48%). This indicated that most participants believed that they 
should sign the consent form if they agreed to take part of the study. Thirty two 
percent (32.5%) responded to all four items, three percent (3.3%) identified three 
items and, nine percent (9.9%) recognized two items. 
 
Our findings showed that participants’ average comprehension scores (58, range: 16-
100) were significantly associated with their level of education (r=0.2216, p=0.0062) 
and income (r=0.2214, p=0.0156). There were no significant correlations between age 
or gender with the total average comprehension scores. 
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Discussion 
 
Examination of the approach used for protecting human subjects participating in 
genetic research has highlighted concerns about its overall effectiveness. We assessed 
subjects’ comprehension of the study protocol, and of risks associated with their 
participation in the EFIND study. Our findings revealed an average comprehension 
score of 58, indicating that some participants gave their consent without fully 
understanding the study protocol and risks. Similarly, in a systematic review, Cohen 
and Larson12 suggested that despite increasing regulatory scrutiny, deficiencies still 
exist in participants’ comprehension of the research in which they participate. In our 
study, we found a strong correlation between educational levels and subjects’ average 
comprehension score. Likewise, previous studies showed that research participants 
with higher education or reading levels had significantly higher understanding scores. 
The differences in understanding due to education were often large, especially 
compared with the improvements produced by the various interventions. For example, 
Taub and Baker13 documented that a feedback intervention increased average 
understanding scores by 29%, but there was a 95% difference between the least 
educated quartile of research participants and the most educated quartile. However, 
they also acknowledged that participants’ recall of the information presented to them 
during the interview may not always reflect their actual understanding of such 
information. 
 
The strong correlation between the level of education and participants’ 
comprehension score is not surprising. Enrolling subjects with a low educational level 
and ensuring a reasonable understanding of the study protocol and risks poses a real 
challenge. In conducting genetic family research over the last decade, we found that 
most subjects were willing to participate in these studies to help researchers and 
advance science. However, high proportions of our research subjects reported a low 
level of education.14 Future studies directed at improving subjects’ understanding of 
risks and ethical issues associated with their participation in genetic research is highly 
recommended. 
 
The most striking finding in our work is the lack of understanding of the social risks 
associated with the GFS. While 35.1% of participants identified all potential physical 
risks, only less than 2% could identify all of the social risks. These findings present 
important implications to obtaining informed consent from subjects participating in 
GFS. Unlike research in which the risks are primarily physical, GFS poses greater 
social risks. The main physical risk in GFS, the drawing of blood, is negligible. 
However, the potential magnitude of social, economic, legal, and psychological harms 
is exceedingly greater. The social and ethical concerns associated with genetic 
research are complicated and pose a real risk for individuals participating in the 
study.15 As a result of a survey conducted in 1995 involving people with a known 
genetic condition in their family, 22% of the participants were denied health insurance 
because of their health status. This denial only represents the reported number and 
does not take into consideration whether or not the participant was already sick.16 
According to the second annual Cogent Research Syndicated Genomics Attitudes & 
Trends (CGAT) Survey conducted by Cogent Research in Cambridge, Massachusetts 
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in 2005,17 the public's greatest concern about genetic testing addresses privacy issues. 
This includes the fear that genetic information will lead to discrimination18. 
 
The IRB requires that consent forms be written at the 6th-grade level, making it 
possible for the participant to understand the scientific aspects associated with the 
study. This becomes more complicated with genetic studies because genetic 
terminology is difficult to phrase in layman’s terms19. According to the CGAT 
survey, there is small number of people who fully understand the concept of 
genomics. Five percent of those who have heard or read something about genomics 
can explain that genetic testing can facilitate early diagnosis. Three percent noted tha
genomics can help customize treatments. This indicates that there is a lack of 
understanding when i 20
t 
t comes to genetics . 
s. 
 
Achieving effective informed consent participation remains a major challenge for 
subjects participating in GFS. Several efforts have been directed to improve 
participants' understanding of information disclosed in the informed consent 
process.21 Some interventions have focused on the use of multimedia.22 Others have 
enhanced the consent form by condensing its length, revising its content, improving 
formatting, and adding graphics.23 Only a few interventions have been directed at 
improving participants’ comprehension of risks and ethical issues associated with 
their participation in genetic research. Previously, we as well as others have suggested 
that having a study team member or a neutral educator spend more time talking one-
on-one to study participants appears to be effective way of improving the 
understanding of subjects regarding the research protocol.24 We proposed a “subject-
centered approach” that viewed enrollment as an active process in which subjects and 
recruiters communicate on risks and ethical issues related to subjects participating in 
genetic research.25 Another way to address the complexity of presenting social risks 
to subjects participating in GFS is to provide visual representations of these risk
Educational aids may include the use of charts, models, DVDs, videotapes, and other 
audio-visual presentations that may assist in communicating the procedures and risks. 
In addition, a semi-tutorial session explaining basic concept of the genetics involved 
with the study could be more effective than reading a consent form alone. For 
complex protocols, the incorporation of diagrams and flow charts into the consent 
document itself may enhance clarifications of the research procedures. 
 
Initiatives to better safeguard the rights and welfare of research subjects participating 
in genetic research require a broader vision. Research volunteers should accurately 
and effectively be informed about what they are getting into.26 Improving the content 
of the consent form is only one aspect of this endeavor, but addressing the complex 
ethical and social implications is the ultimate goal27 for future research in this 
important area. 
 
One potential limitation of this work is the ability to generalize the findings to broader 
groups of multi-ethnic origins. Our intention in this article was not to generalize the 
current findings, but rather to present and describe how a group of low-income 
Mexican-Americans comprehends information about their participation in genetic 
research. Although the broader implications of our findings remain to be 
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demonstrated, we believe they will prove to be especially useful for improving the 
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